DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Survodutide
GLP-1 agonistRx required

Survodutide

Also known as: BI 456906

Investigational dual GLP-1 / glucagon receptor agonist in Phase 3 trials for obesity and MASH.

B
Grade B
Human observational studies
Human studies26
PubMed citations30
Routesubcutaneous
Regulatory (US)Rx required
Last verified2 days ago

Mechanism of action

Peptide dual agonist activating both GLP-1 and glucagon receptors. Glucagon component may increase energy expenditure.

Evidence summary

26
Human studies
30
PubMed citations
24
Clinical trials
B
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Investigational — Phase 3 clinical trials

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07413913Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Pre Filled Pen (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy With Overweight/Obesity (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)Active Not Recruiting · Phase 1 · Healthy · n=56NCT06632444A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver FibrosisRecruiting · Phase 3 · Metabolic Dysfunction Associated Steatohepatitis (MASH) · n=1800NCT06632457A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) CirrhosisRecruiting · Phase 3 · Metabolic Dysfunction Associated Steatohepatitis · n=1590NCT06745284An Active-comparator-controlled, Open-label, Parallel Group Study to Evaluate the Effect of Survodutide on Energy Expenditure and Fatty Acid Oxidation in Subjects With ObesityActive Not Recruiting · Phase 1 · Obesity · n=64NCT05202353Open-label, Randomised, 4 Parallel-group, Phase I Clinical Trial to Investigate BI 456906 Occupancy of Glucagon Receptors in Liver and Glucagon-like Peptide 1 Receptors in Pancreas in Comparison With Semaglutide After Administration of Radiolabeled Tracer in Male and Female Subjects With Obesity Using PET and MRIRecruiting · Phase 1 · Obesity · n=30NCT06309992Multicentre, Randomised, Double-blind, Placebo-controlled, 48-week, Phase III Trial to Evaluate the Efficacy and Safety of Survodutide Administered Subcutaneously in Participants With Overweight or Obesity and Presumed or Confirmed Nonalcoholic Steatohepatitis (NASH)Completed · Phase 3 · Obesity · n=218NCT06077864A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVDActive Not Recruiting · Phase 3 · Obesity · n=5533NCT06066528A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes MellitusActive Not Recruiting · Phase 3 · Obesity · n=755NCT07407348Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)Recruiting · Phase 1 · Healthy · n=80NCT06200467A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group With Nested Crossover Design Trial With Moxifloxacin as Positive Control to Evaluate the Effects of Multiple Subcutaneous Doses of BI 456906 in a Titration Scheme on Cardiac Safety Parameters in (Otherwise) Healthy Male and Female Subjects With Overweight/ObesityCompleted · Phase 1 · Overweight · n=110NCT06564441An Open-label, Non-randomised, Fixed-sequence, Two Period, Phase I Trial to Evaluate the Effect of Different Doses of BI 456906 (Survodutide) on the Single Dose Pharmacokinetics of Bupropion, Caffeine and Midazolam on Otherwise Healthy Volunteers With Overweight or ObesityCompleted · Phase 1 · Overweight · n=34NCT06352411Pharmacokinetics, Safety, and Tolerability of BI 456906 Following Subcutaneous Injection in Male and Female Participants With Mild, Moderate and Severe Renal Impairment in Comparison to Participants With Normal Renal Function (Mono-centric, Open-label Study With Parallel Matched-pair Design)Completed · Phase 1 · Healthy · n=42

Showing 12 of 24 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41054801Son JW, le Roux CW et al. · Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews (2026)HumanPMID 41329105Platz E, Kaplan LM et al. · Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.JACC. Heart failure (2026)PMID 40619099Augustin R, Oldenburger A et al. · Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.Molecular metabolism (2025)HumanPMID 39821928le Roux CW, Steen O et al. · Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.Diabetes, obesity & metabolism (2025)HumanPMID 40364529Zafer M, Tavaglione F et al. · Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.Alimentary pharmacology & therapeutics (2025)HumanPMID 39903735Souza M, Al-Sharif L et al. · Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.Hepatology (Baltimore, Md.) (2025)HumanPMID 40641020Muzurović E, Haluzik M et al. · Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease.Current pharmaceutical design (2025)PMID 40865172Rubio-Herrera MA, Mera-Carreiro S · Weight management treatment in obesity.Medicina clinica (2025)HumanPMID 40557198Awad AA, Abdrabou Abouelmagd A et al. · Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.Proceedings (Baylor University. Medical Center) (2025)PMID 41375628Martínez-Castelao A, Górriz JL et al. · Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.Journal of clinical medicine (2025)PMID 40772898Doiron JE, Elbatreek MH et al. · Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit With GLP-1/Glucagon Agonism.JACC. Basic to translational science (2025)HumanPMID 39952695Kokkorakis M, Chakhtoura M et al. · Emerging pharmacotherapies for obesity: A systematic review.Pharmacological reviews (2025)HumanPMID 39345440Doiron JE, Elbatreek MH et al. · Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit with GLP-1/Glucagon Agonism.bioRxiv : the preprint server for biology (2025)HumanPMID 40081498Bailey CJ, Flatt PR et al. · Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides (2025)HumanPMID 40590228Newsome PN, Loomba R · Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.The Journal of clinical investigation (2025)HumanPMID 38275036Al-Horani RA, Aliter KF et al. · Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.Current diabetes reviews (2024)HumanPMID 39481534Stefanakis K, Kokkorakis M et al. · The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.Metabolism: clinical and experimental (2024)HumanPMID 39400355Kanbay M, Copur S et al. · Glucagon and glucagon-like peptide-1 dual agonist therapy: A possible future towards fatty kidney disease.European journal of clinical investigation (2024)HumanPMID 38330987le Roux CW, Steen O et al. · Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology (2024)HumanPMID 39663847Kaya E, Yilmaz Y et al. · Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.Expert opinion on investigational drugs (2024)Human

Showing 20 of 30 papers. View all on PubMed →